Modulation of p53 activity by IκBα: Evidence suggesting a common phylogeny between NF-κB and p53 transcription factors

BMC Immunology

Volumn 6, Issue , 2005, Pages

  Dreyfus, David H ^a,b   Nagasawa, Masayuki ^a,c   Gelfand, Erwin W ^a   Ghoda, Lucy Y ^d  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; HYBRID PROTEIN; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; TRANSCRIPTION FACTOR RELA;

AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DELETION MUTANT; GENE DELETION; GENE MAPPING; GENE OVEREXPRESSION; IMMUNOMODULATION; IN VITRO STUDY; MOLECULAR PHYLOGENY; NONHUMAN; PRECIPITATION; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RETICULOCYTE LYSATE; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; BURKITT LYMPHOMA; CELL STRAIN COS1; CERCOPITHECUS; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; CONSENSUS SEQUENCE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MULTIGENE FAMILY; MUTAGENESIS; PATHOLOGY; PHYLOGENY; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE; SEQUENCE HOMOLOGY; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANKYRIN REPEAT; BINDING SITES; BURKITT LYMPHOMA; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CONSENSUS SEQUENCE; COS CELLS; EVOLUTION, MOLECULAR; HUMANS; I-KAPPA B PROTEINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; MUTAGENESIS; PHYLOGENY; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE DELETION; SEQUENCE HOMOLOGY, AMINO ACID; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 26444497172     PISSN: 14712172     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-6-12     Document Type: Article

References (81)

1. Ko LJ, Prives C: p53: puzzle and paradigm. Genes Dev 1996, 10:1054-72.
2. Lu H, Fisher RP, Bailey P, Levine AJ: The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol Cell Biol 1997, 17:5923-34.
3. Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, Whittaker K, Demsky M, Fisher WW, Buchman A, Duyk G, Friedman L, Prives C, Kopczynski C: Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell 2000, 101:91-101.
4. Shieh SY, Ikeda M, Taya Y, Prives C: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91:325-34.
5. Soussi T: The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 2000, 910:121-37. discussion 137-9
6. Chipuk JE, Green DR: p53's believe it or not: lessons on transcription-independent death. J Clin Immunol 2003, 23:355-61.
7. Lakin ND, Jackson SP: Regulation of p53 in response to DNA damage. Oncogene 1999, 18:7644-55.
8. Sancar A, Lindsey-Boltz LA, Unsal-Kaccmaz K, Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004, 73:39-85.
9. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Definition of a consensus binding site for p53. Nat Genet 1992, 1:45-9.
10. Mirza A, Wu Q, Wang L, McClanahan T, Bishop WR, Gheyas F, Ding W, Hutchins B, Hockenberry T, Kirschmeier P, Greene JR, Liu S: Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 2003, 22:3645-54.
11. Hulboy DL, Lozano G: Structural and functional analysis of p53: the acidic activation domain has transforming capability. Cell Growth Differ 1994, 5:1023-31.
12. Unger T, Mietz JA, Scheffner M, Yee CL, Howley PM: Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol 1993, 13:5186-94.
13. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992, 256:827-30.
14. Cho Y, Gorina S, Jeffrey PD, Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994, 265:346-55.
15. Brooks CL, Gu W: Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003, 15:164-71.
16. Xu Y: Regulation of p53 responses by post-translational modifications. Cell Death Differ 2003, 10:400-3.
17. Dohoney KM, Guillerm C, Whiteford C, Elbi C, Lambert PF, Hager GL, Brady JN: Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage. Oncogene 2004, 23:49-57.
18. Gu J, Chen D, Rosenblum J, Rubin RM, Yuan ZM: Identification of a sequence element from p53 that signals for Mdm2-targeted degradation. Mol Cell Biol 2000, 20:1243-53.
19. Hupp TR, Sparks A, Lane DP: Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995, 83:237-45.
20. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S: Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004, 36:55-62.
21. Lohrum M, Scheidtmann KH: Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes. Oncogene 1996, 13:2527-39.
22. Sluss HK, Armata H, Gallant J, Jones SN: Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol 2004, 24:976-84.
23. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM: Binding and modulation of p53 by p300/CBP coactivators. Nature 1997, 387:823-7.
24. Scolnick DM, Chehab NH, Stavridi ES, Lien MC, Caruso L, Moran E, Berger SL, Halazonetis TD: CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res 1997, 57:3693-6.
25. Dornan D, Shimizu H, Perkins ND, Hupp TR: DNA-dependent acetylation of p53 by the transcription coactivator p300. J Biol Chem 2003, 278:13431-41.
26. Gu W, Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
27. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T, Lu X: ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001, 8:781-94.
28. Gorina S, Pavletich NP: Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 1996, 274:1001-5.
29. Krzywda S, Brzozowski AM, Higashitsuji H, Fujita J, Welchman R, Dawson S, Mayer RJ, Wilkinson AJ: The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53. J Biol Chem 2004, 279:1541-5.
30. Crook T, Tidy JA, Vousden KH: Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991, 67:547-56.
31. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-36.
32. Doniger J, Muralidhar S, Rosenthal LJ: Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Clin Microbiol Rev 1999, 12:367-82.
33. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T: p53 is frequently mutated in Burkitt's lymphoma cell lines. Embo J 1991, 10:2879-87.
34. Mauser A, Saito S, Appella E, Anderson CW, Seaman WT, Kenney S: The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol 2002, 76:12503-12.
35. Baeuerle PA, Henkel T: Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994, 12:141-79.
36. Baichwal VR, Baeuerle PA: Activate NF-kappa B or die? Curr Biol 1997, 7:R94-6.
37. Green DR: Death and NF-kappaB in T cell activation: life at the edge. Mol Cell 2003, 11:551-2.
38. Kawakami K, Scheidereit C, Roeder RG: Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. Proc Natl Acad Sci U S A 1988, 85:4700-4.
39. Pierce JW, Lenardo M, Baltimore D: Oligonucleotide that binds nuclear factor NF-kappa B acts as a lymphoid-specific and inducible enhancer element. Proc Natl Acad Sci U S A 1988, 85:1482-6.
40. Nolan GP, Ghosh S, Liou HC, Tempst P, Baltimore D: DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide. Cell 1991, 64:961-9.
41. Beg AA, Ruben SM, Scheinman RI, Haskill S, Rosen CA, Baldwin AS Jr: I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention. Genes Dev 1992, 6:1899-913.
42. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y: Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1995, 92:10599-603.
43. DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, Karin M: Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 1996, 16:1295-304.
44. Ghoda L, Lin X, Greene WC: The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J Biol Chem 1997, 272:21281-8.
45. Sun S, Elwood J, Greene WC: Both amino- and carboxyl-terminal sequences within I kappa B alpha regulate its inducible degradation. Mol Cell Biol 1996, 16:1058-65.
46. Grisham MB, Palombella VJ, Elliott PJ, Conner EM, Brand S, Wong HL, Pien C, Mazzola LM, Destree A, Parent L, Adams J: Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome. Methods Enzymol 1999, 300:345-63.
47. Rodriguez MS, Wright J, Thompson J, Thomas D, Baleux F, Virelizier JL, Hay RT, Arenzana-Seisdedos F: Identification of lysine residues required for signal-induced ubiquitination and degradation of I kappa B-alpha in vivo. Oncogene 1996, 12:2425-35.
48. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000, 18:621-63.
49. Scherer DC, Brockman JA, Chen Z, Maniatis T, Ballard DW: Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci U S A 1995, 92:11259-63.
50. Phelps CB, Sengchanthalangsy LL, Huxford T, Ghosh G: Mechanism of I kappa B alpha binding to NF-kappa B dimers. J Biol Chem 2000, 275:29840-6.
51. Beg AA, Sha WC, Bronson RT, Baltimore D: Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes Dev 1995, 9:2736-46.
52. . Klement JF, Rice NR, Car BD, Abbondanzo SJ, Powers GD, Bhatt PH, Chen CH, Rosen CA, Stewart CL: IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. Mol Cell Biol 1996, 16:2341-9.
53. Webster GA, Perkins ND: Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 1999, 19:3485-95.
54. Egan LJ, Eckmann L, Greten FR, Chae S, Li ZW, Myhre GM, Robine S, Karin M, Kagnoff MF: IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci U S A 2004, 101:2452-7.
55. Holmes-McNary MQ, Baldwin AS Jr, Zeisel SH: Opposing regulation of choline deficiency-induced apoptosis by p53 and nuclear factor kappaB. J Biol Chem 2001, 276:41197-204.
56. Jung M, Zhang Y, Lee S, Dritschilo A: Correction of radiation sensitivity in ataxia telangiectasia cells by a truncated I kappa Balpha. Science 1995, 268:1619-21.
57. Perkins ND: Oncogenes, tumor suppressors and p52 NF-kappaB. Oncogene 2003, 22:7553-6.
58. Rocha S, Campbell KJ, Perkins ND: p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol Cell 2003, 12:15-25.
59. Ryan KM, Ernst MK, Rice NR, Vousden KH: Role of NF-kappaB in p53-mediated programmed cell death. Nature 2000, 404:892-7.
60. Jeffrey PD, Gorina S, Pavletich NP: Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995, 267:1498-502.
61. Muller CW, Harrison SC: The structure of the NF-kappa B p50:DNA-complex: a starting point for analyzing the Rel family. FEBS Lett 1995, 369:113-7.
62. Muller CW, Rey FA, Sodeoka M, Verdine GL, Harrison SC: Structure of the NF-kappa B p50 homodimer bound to DNA. Nature 1995, 373:311-7.
63. Yang JP, Hori M, Takahashi N, Kawabe T, Kato H, Okamoto T: NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene 1999, 18:5177-86.
64. Dreyfus DH, Nagasawa M, Kelleher CA, Gelfand EW: Stable expression of Epstein-Barr virus BZLF-1-encoded ZEBRA protein activates p53-dependent transcription in human Jurkat T-lymphoblastoid cells. Blood 2000, 96:625-34.
65. Gutsch DE, Holley-Guthrie EA, Zhang Q, Stein B, Blanar MA, Baldwin AS, Kenney SC: The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B. Mol Cell Biol 1994, 14:1939-48.
66. Morrison TE, Mauser A, Klingelhutz A, Kenney SC: Epstein-Barr virus immediate-early protein BZLF1 inhibits tumor necrosis factor alpha-induced signaling and apoptosis by downregulating tumor necrosis factor receptor 1. J Virol 2004, 78:544-9.
67. Sun SC, Elwood J, Beraud C, Greene WC: Human T-cell leukemia virus type I Tax activation of NF-kappa B/Rel involves phosphorylation and degradation of I kappa B alpha and RelA (p65)-mediated induction of the c-rel gene. Mol Cell Biol 1994, 14:7377-84.
68. Chang NS: The non-ankyrin C terminus of Ikappa Balpha physically interacts with p53 in vivo and dissociates in response to apoptotic stress, hypoxia, DNA damage, and transforming growth factor-beta 1-mediated growth suppression. J Biol Chem 2002, 277:10323-31.
69. Zhou M, Gu L, Zhu N, Woods WG, Findley HW: Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene 2003, 22:8137-44.
70. Foo SY, Nolan GP: NF-kappaB to the rescue: RELs, apoptosis and cellular transformation. Trends Genet 1999, 15:229-35.
71. Hogue CW: Cn3D: a new generation of three-dimensional molecular structure viewer. Trends Biochem Sci 1997, 22:314-6.
72. Malek S, Huang DB, Huxford T, Ghosh S, Ghosh G: X-ray crystal structure of an IkappaBbeta × NF-kappaB p65 homodimer complex. J Biol Chem 2003, 278:23094-100.
73. Merrick BA, Zhou W, Martin KJ, Jeyarajah S, Parker CE, Selkirk JK, Tomer KB, Borchers CH: Site-specific phosphorylation of human p53 protein determined by mass spectrometry. Biochemistry 2001, 40:4053-66.
74. Bessard AC, Garay E, Lacronique V, Legros Y, Demarquay C, Houque A, Portefaix JM, Granier C, Soussi T: Regulation of the specific DNA binding activity of Xenopus laevis p53: evidence for conserved regulation through the carboxy-terminus of the protein. Oncogene 1998, 16:883-90.
75. Sakaguchi K, Sakamoto H, Xie D, Erickson JW, Lewis MS, Anderson CW, Appella E: Effect of phosphorylation on tetramerization of the tumor suppressor protein p53. J Protein Chem 1997, 16:553-6.
76. Akslen LA, Morkve O: Expression of p53 protein in cutaneous melanoma. Int J Cancer 1992, 52:13-6.
77. Dreyfus DH, Nagasawa M, Pratt JC, Kelleher CA, Gelfand EW: Inactivation of NF-kappaB by EBV BZLF-1-encoded ZEBRA protein in human T cells. J Immunol 1999, 163:6261-8.
78. Bohuslav J, Chen LF, Kwon H, Mu Y, Greene WC: p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem 2004, 279:26115-25.
79. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG: Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 1997, 94:12616-21.
80. Stefanovic D, Erikson E, Pike LJ, Maller JL: Activation of a ribosomal protein S6 protein kinase in Xenopus oocytes by insulin and insulin-receptor kinase. Embo J 1986, 5:157-60.
81. Bonsing BA, Corver WE, Gorsira MC, van Vliet M, Oud PS, Cornelisse CJ, Fleuren GJ: Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry. Cytometry 1997, 28:11-24.